Adcock Ingram Integrated Report 2016

41 / 182

SALES
Public sector
18%
82 % TOP 10 BRANDS
TURNOVER
R610
MILLION
TRADING
PROFIT
R171
MILLION
(2015: R148m)
Private sector
OVERVIEW
The portfolios of products are
grouped according to therapeutic
areas in order to facilitate
promotion to relevant specialities:
The division has three broad areas:
Generics Ethical
• Lengthy registration timelines impacting on
patient access to new and low cost treatments
• Global decline in new product pipeline with
multinational companies launching clones
• Consolidation and mergers of large companies
within the industry
• Funders encourage switching to generics
• Significant HIV disease burden
MARKET TRENDS BUSINESS FOCUS TOP TEN BRANDS
• The multinational partner of choice
• Secure and deliver an innovative high value
pipeline
• Grow the generics portfolio
• Build a leading local manufacture ARV franchise
• Trivenz
• Genpayne
• Adco-Zolpidem
• Myprodol
• Estrofem
• Cipralex (Lundbeck)
• Adco-Simvastatin
• Lamivudine/Zidovudine
• Adco-Efavirenz
• Xylotox
The generic portfolio is the largest by value in the Prescription division.
External data shows that Adcock Ingram is the 4th ranked generic
manufacturer in the prescription market with a share of 8.6% and is growing
ahead of the market.
Genpayne is the leading brand in the portfolio. The performance of the
ARV portfolio, particularly in the private sector, is very encouraging. With a
market share of 12,1%, the ARV portfolio is growing at 54%. Trivenz, the triple
combination, is the most significant growth contributor.
The branded portfolio is performing strongly with value growth of 11.8%, ahead of
the market growth of 5.5%.
Strategic Alliances
Strategic alliances with multinational companies (MNC) are an important part
of the Prescription business. Despite high levels of genericisation, this portfolio
continues to grow steadily.
Generics
Gastrointestinal
Pain
CNS
Urology
ARV
Women’s
Health
Dermatology
Cardiovascular
Ophthalmics
PERFORMANCE
FIVE SIX THREE ONE FOUR TWO OUR PERFORMANCE (continued)
| 37
Integrated Report 2016